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4Management of severe aortic valve 
stenosis in the neonate
AS may occur in isolation, or in association with other congenital 
cardiac defects. These include other left heart obstructive lesions in 
Shone association and the hypoplastic left heart syndrome (HLHS) 
as well as septal defects. It may also occur with extra-cardiac 
malformations of the renal, gastrointestinal and central nervous 
systems.(5) The LVOTO is mainly at the level of the annulus (70%) 
but may also occur at sub-valvar or supra-valvar levels. 
EMBRYOLOGY OF THE SEMI-LUNAR VALVES
The semi-lunar valves develop from the fourth week of gestation. 
Neural crest cells from the fourth and sixth pharyngeal arches 
migrate into the truncus arteriosus and conus cordis and transform 
into mesenchymal tissue that proliferates to form 2 truncoconal 
cushions. These 2 endocardial cushions or ridges appear opposite 
each other in the upper part of the truncus arteriosus, in the 
dextro-superior and sinistro-inferior positions, and fuse to form 
the truncal septum. Simultaneously, another 2 intercalated endo-
cardial cushions form, each at 90º from the first 2 (Figure 1). Further 
cavitation of the ridges (Figure 2) form the 3 triangular-shaped 
leaflets in each outflow tract: the truncal septum differentiates to 
form the left and right aortic valve cusps and 2 of the leaflets of 
the pulmonary valve, and the additional 2 endocardial cushions also 
evolve, with the right cushion forming the posterior aortic valve 
cusp, and the left the anterior pulmonary valve leaflet. This occurs 
during the anti-clockwise rotation and caudal shifting of the cono-
truncus. The formed semi-lunar valves are thus usually trileaflet 
with the pulmonary valve’s cusps orientated left, right, and anterior 
and the aortic valve’s cusps left, right and posterior. The endocardial 
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Severe or critical aortic stenosis (AS) in the neonate represents a 
cardiac emergency. Unless the diagnosis is made in utero or at 
delivery, the baby may be discharged home presenting later in 
extremis when the ductus arteriosus (DA) closes. Management of 
severe AS is aimed at quickly, safely and adequately reducing the 
severity of the left ventricular outflow tract obstruction (LVOTO) 
whilst maintaining the greatest degree of aortic valve integrity and 
left ventricular function.
BACKGROUND
Congenital AS comprises 5% of congenital heart defects, with inci-
dences ranging from 0.04 to 0.38 per 1 000 live births.(1,2) There is 
a clear male predominance with a male to female ratio of 4:1.(3) The 
transmission risk is greater if the affected parent is the mother 
(recurrence risk ~3% and ~15% in children of an affected father or 
mother respectively). This defect occurs sporadically in most cases. 
There is an association with Turner Syndrome (45XO) and rarely 
in William Syndrome (7q11 del). Autosomal dominant inheritance 
may be associated with mutations in the NOTCH1 gene.(4) 
Aortic valve stenosis (AS) causing obstruction to the left 
ventricular outfl ow, and hence reduction of the cardiac out-
put, remains a therapeutic challenge for paediatric cardi-
ologists and cardiothoracic surgeons. 
Infants that present at birth may have very dysplastic valves 
with severe or critical AS and are typically the most diffi cult 
to treat.  This article therefore focuses on the management 
of severe AS in the neonate. This article also revises the 
embryology of the semi-lunar valves, as the morphology 



















cushions also transform histologically from a primitive myosin-heavy 
chain to an alpha-smooth muscle actin phenotype: the mature 
semi-lunar valve leaflets, which are thinner and more pliable. 
Many of the pathways involved in the formation of the semi-lunar 
valves, especially the role of mesenchymal transformation, are still 
being explored. Correct valve formation requires proliferation of 
endocardial cushion tissue, yet this must also be limited to ensure 
that the cushions can be remodelled to form thin cusps. Congenital 
abnormalities of the aortic valve such as bicuspid, unicuspid and 
dysplastic valves are thus thought to be the result of failure of 
the truncoconal neural crest tissue migration, of incorrect fusion 
and/or of incomplete transformation and differentiation of the 
endocardial cushions.(6,7)
PATHOLOGY
Aortic valves may be morphologically unicuspid (functionally or 
true), bicuspid (functionally or true), tricuspid (normal) (Figure 3) 
or rarely quadricuspid.(8)
Bicuspid aortic valves (BAV) are common and occur in 0.5 - 2% of 
the population with a 2:1 male predominance.(9) The incidence may 
be as high as 10% in some families. An exact inheritance pattern 
has yet to be determined. Currently, it is thought that bicuspid 
valves are due to the interaction of multiple genes causing abnor-
mal root structure.(10) BAV may occur in isolation or in association 
with patent ductus arteriosus (PDA), coarctation of the aorta, 
Williams syndrome (rare) and  Turner syndrome. Animal studies 
have demonstrated a complex interaction between intracellular 
pathways and individual stem cells rather than just faulty fusion 
of cusps.(5) Various forms of BAV have been described with the 
anterior-posterior formation being the most common.(11,12) BAV 
can develop stenosis and/or incompetence, as well as ascending 
aorta aneurysms and dissections.(13) Only a quarter of patients will 
have normal valve function and will require no intervention.(14,15)
Unicuspid aortic valves (UAV) are less common and occur in only 
approximately 1 of 10 000 population.(16) They are associated with 
significant aortic stenosis. An estimated 50% of individuals with 
FIGURE 1: Embryology of the Semi-lunar valves*
P = Posterior, A = Anterior, L = Left, R = Right.




















FIGURE 2: Embryology of the Semi-lunar cusps*
*  Adapted from http://embryology.med.unsw.edu.au/embryology/indexphptitle=
File:Semilunar_Cusps.jpg
FIGURE 3: Aortic valve variations of morphology as seen in 











*  Reproduced with permission from Maskatia, et al. Catheter Cardiovasc Interv. 2013;
81:90-95. Wiley
6UAV also have dilation of the ascending aorta.(17) All valves have 
a single posterior commissural attachment. The free edge of the 
valve extends from the single commissure without further con-
nection to the aorta. 
Quadricuspid aortic valves (QAV) are rare, occurring in only 1-10 
patients per 100 000 population, with a slight male predomi-
nance.(18) This condition was first described by Balington in 1862 
and can affect both the pulmonary and aortic valves in a 10:1 ratio.(19) 
Unlike BAV, aortic stenosis is rare. Significant aortic valve incom-
petence, secondary to a central malcoaptation of the 4 valve 
leaflets, is commonly observed in QAV. 
In the severely dysplastic valve, no normal valve leaflets or anatomy 
may be distinguishable. Balloon dilation of the aortic valve in this 
situation, even with a high-pressure, non-compliant balloon, is 
seldom successful. The valve tissue recoils back to its original 
position once the balloon is deflated. Open surgical valvotomy 
with debulking of the leaflets has a far better outcome for this 
subset of patients.(20,35) 
MANAGEMENT
The aim of all AS treatment is to preserve the function of the 
aortic valve and the left ventricle for as long as possible.
Medical management
Neonates with severe or critical AS have decreased cardiac output 
and need urgent haemodynamic support. Resuscitation with fluids 
and a continuous infusion of alprostadil at a dose of 0.01-0.1mcg/
kg/min IVI must be started without delay. Alprostadil produces 
vasodilation of the DA smooth muscle and increases cardiac output. 
Opening and maintaining the patency of the DA will ensure 
adequate systemic blood flow and perfusion of the vital organs. The 
infant should be monitored for side-effects, specifically apnoea 
episodes (12%). Apnoea is seen most often in neonates with a low 
birth weight <2kg, at higher dosages and usually appears during 
the first hour of administration. Other adverse effects include: fever 
(14%), bradycardia (7%), hypotension (4%), seizures (4%), tachy-
cardia (3%), diarrhoea (2%) and sepsis (2%). Hypokalemia and 
cardiac arrest occur in <1% of patients.(21)
Infants with dyspnoea, tachypnoea and increased work of breath
ing may have pulmonary oedema secondary to raised left ventricle 
end-diastolic and left atrial pressures, and may need respiratory 
support with intubation and positive pressure ventilation. Loop 
diuretics such as furosemide may be given intravenously in small 
doses.(20) 
In neonates with severe AS with low cardiac output and decreased 
LV function, inotropic support in the form of continuous infusions 
of dopamine or dobutamine is indicated. Drugs that cause signi-
ficant vasodilation should be avoided as they may cause hypoten-
sion, especially in the low birth weight infant with a small aortic 
valve area. 
Once stabilised, the infant should be referred for urgent interven-
tion to reduce the severity of the LVOTO.
Interventional management
The stenosis of the aortic valve may be addressed by either balloon 
valvuloplasty (BV) or surgical valvotomy (SV). In recent years a third 
alternative, hybrid intervention, has emerged as a palliative measure 
for infants with borderline hypoplastic left heart dimensions. This 
entails balloon atrial septostomy with stenting of the PDA by the 
paediatric cardiologist with pulmonary artery banding by the 
cardiothoracic surgeon.
The choice of treatment should be guided by evidence-based 
reviews; local experience and skills. It is usually dictated by the 
morphology of the aortic valve, the size and function of the left 
heart, the presence of associated defects and the overall condition 
and weight of the neonate. The key issue is to decide whether the 
left heart structures are adequate to sustain the systemic circula-
tion, i.e. a biventricular repair,(22) and if so, what intervention will 
be the most beneficial for the individual neonate.(23,24) The pros and 
cons of each intervention have been the subject of many publi-
cations.(25,26,27,28,29,30) 
Many studies have been published comparing the results of SV vs. 
BV for severe congenital AS. Outcomes such as longterm survival, 
incidence of aortic valve re-stenosis, residual stenosis or insufficiency 
(or both), freedom from re-operation and death or need for trans-
plantation have been compared.(31) 
Brown, et al. were in favour of SV as the primary management for 
severe AS (although they excluded infants <2 months’ age and thus 
arguably the worst morphology as these all underwent open SV 
(Table 1).(20) There was no significant difference in the character-
istics of the 2 groups as regards age, body surface area, valve 
anatomy and gradient. They demonstrated that gradient reduction, 
aortic incompetence (AI), and the need for re-intervention were 
worse for BV. Kaplan-Meier analysis at 10 years of SV vs. BV 
showed freedom from re-intervention as 72% vs. 53% and 
freedom from AVR 80% vs. 75%. They concluded that BV has less 
reduction in gradient, more residual AI, and a shorter interval 
between subsequent re-interventions than SV. Further they 


















showed that SV is safe and effective with low residual amounts 
of AS and AI, allowing AVR to be delayed until the child is 
older. A summary of several studies of BV and SV are shown in 
Tables 2 and 3.(20)
SURGICAL VALVOTOMY (SV)
Although surgical aortic valvotomy, transventricular without cardio-
pulmonary bypass (CPB) or open valvotomy with CPB, was 
previously perceived as extremely high risk with significant mor-
bidity and mortality, it is now considered to be relatively safe and 
effective.(32) 
Absolute indications for surgical management include the need for 
a single ventricle repair and the presence of additional defects that 
can only be addressed surgically e.g. small aortic annulus, sub- or 
supra-valvar aortic stenosis, coarctation, etc. The infant is thus 
assessed for suitability for a biventricular circulation using various 
protocols and scoring systems based variously on mitral valve 
diameter, indexed aortic root diameter, indexed MV area, indexed 
LV mass, LV inflow structures, morphology of the LVOT, length of 
the LV, presence and degree of EFE, and functional variables such 
as reversed flow in the ascending aorta and LV function.(33,34) None 
of these scoring systems have proven to be completely accurate. 
Predominantly reversed flow in the ascending aorta, particularly 
associated with decreased LV function, is ominous and a single 
ventricle repair (palliation) should be considered. In contrast, 
predominantly prograde flow in the ascending aorta and transverse 
arch correlates well with survival after a biventricular repair.(27) 
A small mitral valve orifice is a well-known risk factor for death.(26,30) 
Therefore, if the mitral valve annulus diameter is less than 7mm (or 
less than the – 2 z-score), or if there is severe LV inflow obstruction, 
one should consider a single ventricle palliation, and eventually 
attempt to promote growth if the rest of the LV is well developed. 
In addition, hypoplasia of the aortic annulus (<5mm), a ratio of 
left to right ventricular lengths of <0.8, a cardiac apex not formed 
by the LV, and the presence of endocardial fibroelastosis (EFE) are 
contra-indications for SV (and BV).(25,26) However, if some of 
these variables are correctable and biventricular repair is still 
feasible, the Ross/Ross-Konno operation is an option when the 
child is older.(25,28) 
TABLE 1: Outcome related to morphology.(8)
* Statistically significantly different as compared to the total group, P value <0.05.
Morphology AI Re-BAV AVR Death /  Any TOTAL 
    TP event
Functionally 24(26%) 4(4%)* 7(8%)* 2(2%)* 13(14%)* 92 
Bicuspid 
True  6(46%) 1(8%) 6(46%)* 1(8%) 7(5%)* 13
Bicuspid 
Functionally  8(40%)  7(35%)* 6(30%)* 1(5%) 10(50%)* 20
Unicuspid 
True  2(33%)  2(33%) 0 3(50%)* 4(67%)* 6
Unicuspid 
Dysplastic 4(25%)  5(31%)* 2(13%) 3(19%) 6(38%) 16
TOTAL 44/147  19/147 21/147 10/147 40/147 147
 (30%)  (13%)  (14%)  (7%)  (27%)
TABLE 2: Surgical Aortic Valvotomy (Literature review).(20)
Reference Year Patients Age  Time  Mortality Re-do
   (Mean) interval  overall  pro-
    (y)  cedure
Justo(36) 1996 90 n/a 3.6  15(17%) 44%
Chartrand(25) 1999 67 8.8 10.6 3(5%) 24%
Lambert(37) 2000 121 2.4 9,.4 15(21%) 50%
Detter(26) 2001 116 13.7 23.8 25% 32%
Bogers(56) 2001 11 2.7 4.8 1(19%) 36%
Alexiou(28) 2001 44 6.8 10.0 0 18%
Tweddel(52) 2005 47 9.9 n/a 0 13%
Brown(20) 2012 89 7.1 9.8 2(5) 43%
TOTAL  566  10.3 12%  34%
     (3-25)  (13-50)
TABLE 3: Balloon Valvuloplasty (Literature review).(20)
Reference Year Patients Age  Time  Mortality Re-do
   (Mean) interval  overall  pro-
    (y)  cedure
Justo(36)  1996 107 5.7 3.1 2% 27%  
      (28/105)
Borghi(38)  1999 90 13.7 5.1 16% 48% 
      (39/81)
Jindal(57)  2000 74 n/a 5.5 0% 14% 
      (10/74)
Balmer(51)  2004 70 2.2 1.7 9% 35% 
      (24/68)
Reich(58)  2004 269 n/a 5.3 10% 29%  
      (78/269)
Brown(44)  2010 509 2.4 9.3 9% 44%  
      (225/509)
Brown(20) 2011 69 6.7 5.2 3% 47% 
      (32/68)
Total  1 188   5 7% 35%
     (range  (range
     0%-16%) 14%-48%)
8A relative indication for surgery is a very bulky and dysplastic aortic 
valve. These valves have no clear leaflets or commissures and are 
fibrous and firm. BV, even with high pressure non-compliant 
balloons, often yields unsatisfactory results.(18) SV has the added 
benefit of visual identification of the commissures, if present, making 
precise surgical division possible. In addition any thick leaflet nodules 
can be shaved off and the leaflets thinned, giving better mobility of 
the leaflets during systole and coaptation during diastole.(17) Inter-
leaflet triangles and even neocommisures may be created.(35)
Several large studies have been published about the longterm 
follow up of neonates and infants that underwent SV for severe 
or critical AS. Alexiou, et al. published their data from 18 conse-
cutively enrolled neonates who had open commissurotomies for 
critical AS.(28) There were no operative deaths and the mean 
gradient at discharge was <40mmHg. Six infants had mild and 2 
had moderate AI. Kaplan-Meier 5- and 10-year freedoms from 
any aortic re-operation or re-intervention were 85% and 55%, 
respectively; 5- and 10-year freedoms from aortic valve replace-
ment were 100% and 79%, respectively. Kaplan-Meier 10-year 
survival was 100%. All their patients are leading normal lives and 
are in New York Heart Association class I. They conclude that 
SV for critical aortic stenosis in neonates has little risk and yields 
good freedom from recurrent AS or AI. The study published by 
Detter, et al., although based on the follow up over 3 decades of 
67 slightly older children, showed that congenital AS in children 
can be controlled surgically until adulthood.(26)
BALLOON VALVULOPLASTY (BV)
In neonates, the aim of BV is to adequately relieve the LVOTO 
without causing significant AI, and restoring normal LV function. As 
cardiac catheterisation techniques and equipment have improved, 
percutaneous balloon valvuloplasty can now be safely performed 
with little mortality and minimal morbidity and has become the 
intervention of choice in most centres for severe congenital AS.(38) 
Neonates with critical AS on alprostadil should be kept sedated 
and intubated before the BV, to maintain haemodynamic stability 
during the procedure. In critically ill infants in whom the DA has 
closed, surgical and ECMO backup should be readily available.
Several methods of arterial accesses for aortic BV have been 
described over the last 2 decades, although no consensus has been 
reached as to which is optimal in the neonate. These include retro-
grade approaches via the femoral artery, the right subscapular 
artery, the umbilical artery, or the right carotid artery, as well as 
the prograde transvenous approach through the atrial septum via 
the foramen ovale.(39,40,41) 
The advantages of the subscapular, carotid or umbilical arterial 
approaches, as well as the transvenous approach, include sparing of 
the femoral arteries for later re-intervention and reduced risk of 
femoral artery spasm or occlusion. This still occurs despite the use 
of very low profile balloon catheters (sheaths as small as 3F are 
now available for use in neonates). The disadvantages include the 
small size of these vessels as well as the often-winding route via 
the umbilical artery. The transvenous prograde approach can also 
be challenging if the LV is small or hypertrophied. Care must be 
taken not to damage the mitral valve apparatus.
BV of the aortic valve via the right carotid artery is technically easy, 
although a surgical cut-down and repair of the vessel is usually 
required. This procedure has been described in the ICU under 
transesophageal echocardiographic (TEE) guidance, if neonatal 
size probes are available. This offers the advantages of contin-
uous haemodynamic monitoring, continuous assessment for AI, 
no exposure to fluoroscopy and no need to transport a sick 
neonate to and from the catheterisation laboratory.(42) 
Great care must be taken during BV to avoid over-zealous dilation 
that would result in damage to the aortic valve and subsequent 
AI.(43) BV produces a tear at the weakest part of the aortic valve, 
which is often not at the fused commissures. AI may result from 
commissural avulsion, cusp dehiscence, cusp tears or perforation. 
Brown et al. found that a lower post-dilation AS gradient and less 
post-dilation AI led to longer freedom from aortic valve replace-
ment (AVR).(44) The difficulty faced in the catheterisation labora-
tory is usually the decision as to when to upsize (or not) the 
balloon, especially in patients with moderate residual gradients of 
30 to 40mmHg. Increasing the balloon size may lead to a lower 
residual gradient and therefore longer freedom from AVR. 
However, this may also result in an increased amount of AI which 
would cancel out the above benefit.(45) A balloon diameter to aortic 
valve annulus diameter ratio of 0.9:1 is recommended and should 
not be exceeded. 
Maskatia, et al. reported their 25 year experience with BV for con-
genital aortic stenosis.(46) A retrospective single-institution review 
was performed and the following end points were evaluated: mod-
erate or severe aortic insufficiency (AI) on echo, AVR, re-do BV, 
SV, transplantation or death. From 1985 to 2009, 272 patients 
who underwent BAV at ages 1 day to 30.5 years were followed for 
5.8 ± 6.7 years. Transplantation or death occurred in 24 patients 
(9%) and was associated with depressed LV function. Forty-two 
patients (15%) needed AVR at a median of 3.5 years; this was 
associated with residual AS ≥25mmHg (p=0.02), post-BAV AI 


















(p=0.03), and depressed LV function (p=0.04). AI was found in 83 
patients (31%) and was inversely related to post-BV gradient 
≥25mmHg and was associated with depressed baseline LV func-
tion. Neonates, patients with post-BV gradients ≥25mmHg, and 
patients with lower baseline LV function experienced worse 
outcomes.
Brown, et al. followed up 509 patients with a cumulative follow-up 
of 5 003 patient years. Although peak AS gradients decreased well 
after dilation, 14% of patients had moderate or severe AI. Survival 
free from aortic valve re-intervention was 1% at 1 year, 2% at 
5 years, 3% at 10 years, and 3% at 20 years. Freedom from AVR 
was 2% at 5 years, 3% at 10 years, and 4% at 20 years. After 
multivariate analyses, lower post-dilation AS gradient grade of AI 
were associated with longer freedom from AVR, but age and pre-
dilation AS severity were not. They conclude that although BV is 
effective for relief of congenital AS, there are steady long-term 
hazards for surgical re-intervention and replacement.(42)
The amount of residual aortic stenosis or incompetence after SV 
or BV is an important predictor of the infant’s long-term outcome 
and significantly affects the quality of life.(47) Neonates undergoing 
SV are more likely to have residual stenosis, particularly in uni-
cuspid or bicuspid valves. This residual AS can however, have a 
positive effect on the growth of the LV and the annulus of 
the aortic valve.(48) Conversely, AI is more common after BV.(49) 
McElhinney, et al. found that infants with post-BV AI had a more 
rapid increase in LVED z-scores at follow-up.(50) Even mild residual 
AI is a risk factor for progressive AI and ventricular dysfunction 
and may require earlier AVR.(31,51)
AORTIC VALVE REPLACEMENT (AVR)
The majority of patients with severe AS will need further surgery 
after either BV or SV. This may take the form of eventual aortic 
valve repair, replacement or even cardiac transplantation. The 
presence of severe residual stenosis or incompetence after BV and/
or SV, LV dilation and decrease in LV function are indications for 
AVR. This is put off as long as possible in small children with small 
aortic annuli, whilst closely monitoring LV function. This ensures a 
better patient-valve match for increased valve longevity and interval 
between re-do replacements.
The 3 options for eventual AVR are: mechanical prosthetic valves, 
bioprosthetic valves and the Ross procedure. Recently a fourth 
option has become available, namely transcutaneous aortic valve 
implantation (TAVI). The management of anticoagulation (in preg-
nancy and other), teratogenic effects of warfarin, anticipated need 
for re-operation or re-intervention, etc. should be extensively 
discussed with the patient and family beforehand.
Mechanical prosthetic valves are long lasting but require lifelong 
anticoagulation. If implanted too early, they have a greater potential 
for early development of patient-prosthesis mismatch.
The bioprosthetic valves (bovine, porcine, and cadaver homografts) 
do not need anticoagulation but are less durable. They may be 
considered in patients with contra-indications to mechanical valves 
and anticoagulation. 
The Ross procedure is an auto-transplantation of the pulmonary 
valve to the aortic position, with the insertion of a pulmonary 
homograft in the pulmonary position. It allows growth of native 
tissue and avoids the need for anticoagulation and many sport 
restrictions. Unfortunately, children tend to develop early calcific 
stenosis and/or insufficiency of the pulmonary homograft. This can 
lead to repeated interventional catheterisations or surgical re-
operations to relieve the RVOTO. Percutaneous pulmonary valve 
implantation (PPVI) is now available for older children and adults 
and can reduce the need for multiple surgical pulmonary conduit 
replacements.
TAVI is currently not an option for small children as the delivery 
system is too large. Longterm follow-up data is also limited. 
Some units advocate aortic valve repair rather than replacement. 
The advantages of valve repair obviously include increased poten-
tial for growth, preservation of the pulmonary valve as a later 
option for the Ross procedure, lack of anticoagulation and delay of 
AVR. The disadvantages include significant residual stenosis or 
insufficiency. 
Tweddell, et al. demonstrated that complex aortic valve repair 
achieves intermediate outcomes similar to those of aortic valve 
replacement (see Table 4).(52) They suggest further studies to 
determine long-term outcomes and to better identify candidates 
for valve repair. At present valve repair is considered for patients 
with an adequate aortic annulus, without extensive leaflet destruc-
tion, and with the potential for a satisfactory result with a minimum 
of prosthetic material. 
UNIVENTRICULAR REPAIR
Infants with anatomy precluding a biventricular repair or with 
severe LV dysfunction may be palliated with a staged univentricular 
approach such as the Norwood procedure. Stage 1 involves anasto-
mosis of the pulmonary artery to the aortic arch to increase 
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systemic outflow, placement of either a systemic-to-pulmonary 
arterial shunt or RV to PA conduit to provide pulmonary blood 
flow, and atrial septectomy to ensure unobstructed pulmonary 
venous return. Stage 2 is a bidirectional Glenn with anastomosis of 
the superior vena cava to the pulmonary arteries. Stage 3 is the 
Fontan completion with conduit anastamosis of the IVC to the 
pulmonary arteries. The overall survival with the Norwood repair 
varies according to institution. More than 50% of survivors have 
neurodevelopmental impairment.(53)
CONCLUSION
The management of severe or critical AS in the neonate is 
challenging. Recent editorials written by Neil Wilson and Carl 
Backer conclude that there is still no clear-cut treatment of 
choice.(54,55) The decision whether to opt for surgical or balloon 
valvuloplasty must be guided by the morphology of each individual 
aortic valve. All treatment modalities have their advantages and 
disadvantages with a current slant towards open surgical valvo-
tomy.(33) Re-interventions and re-operations are inevitable and 
expected, but if managed carefully, aortic valve replacement can 
be avoided or delayed until the implantation of an adult-sized 
prosthesis is possible. 
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NEONATAL AORTIC VALVE STENOSIS
TABLE 4:   Results of complex aortic valve repair versus valve
 replacement.(52)
 Repair AVR p-value
No. 57 57  
Age at operation 9.4 ± 7.9 12.4 ± 8.3 .049
Previous intervention  25% 37% .20
Indication:  AS 35% 16%  
               AI 32% 42%  
               AS and AI 33% 42%  
Residual gradient 20 ± 21 12.5 ± 25 .10
AI mild or less 67% 84% .07
AI moderate or less 94% 92% .72
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